European Heart Journal Advance Access originally published online on February 21, 2007
European Heart Journal 2007 28(6):692-698; doi:10.1093/eurheartj/ehl564
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial
1 Department of Cardiology and Medical Sciences, Uppsala University Hospital, Uppsala, Swedon
2 AstraZeneca R + D, Mölndal, Sweden
3 Clinical Chemistry, Uppsala University Hospital, Uppsala, Swedon
4 Uppsala Clinical Research Center, Uppsala, Sweden
Received 16 March 2006; revised 29 January 2006; accepted 1 February 2007; online publish-ahead-of-print 21 February 2007.
* Corresponding author. Tel: +46 18 611 90 68; fax: +46 18 50 66 38. E-mail address: christina.christersson{at}akademiska.se
Aim Patients with a recent myocardial infarction have an increased risk of recurrent ischaemic events. In the ESTEEM trial, the oral direct thrombin inhibitor ximelagatran reduced the risk of new ischaemic events when compared with placebo in aspirin treated post myocardial infarction patients. Ximelagatran persistently reduced markers of coagulation activity, i.e. prothrombin fragment 1 + 2 (F1 + 2) and D-dimer levels. The aim of this substudy was to evaluate the levels of these markers and activated thromboplastin time (APTT) in relation to new ischaemic events or bleeding.
Methods and results In the substudy, 518 out of 1883 patients were included and within 14 days after a myocardial infarction randomized to ximelagatran or placebo for 6 months. The clinical endpoints death, myocardial infarction, severe recurrent ischaemia, ischaemic stroke, and bleeding were evaluated. The levels of F1 + 2, D-dimer, and APTT were analysed at randomization and in serial samples during the study. Ximelagatran treatment appeared to have a larger treatment effect in patients with F1 + 2 and D-dimer levels above the median at randomization with a reduction of ischaemic events from 18 to 9% (P = 0.03) for F1 + 2 and from 20 to 9% for D-dimer (P = 0.009). A reduction of D-dimer levels was found in 60% of the patients 1 week after randomization and these patients had less ischaemic events when compared with patients with unchanged or increased levels (P = 0.03) regardless of treatment. F1 + 2 and D-dimer levels were unrelated to bleeding risk. In the ximelagatran group, increased APTT was not related to ischaemic events but associated with a raised risk of bleeding.
Conclusion A reduction of initially high coagulation activity, as measured by the D-dimer level, in patients with recent myocardial infarction identifies patients with a decreased risk of new ischaemic events, regardless whether the reduction occurs spontaneously or is induced by pharmacological means. Patients with higher initial coagulation activity seemed to benefit most from long-term treatment with ximelagatran.
Key Words: Myocardial infarction • Ischaemic event • Coaguulation activity • Direct thrombin inhibitor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Christersson, J. Oldgren, A. Bylock, A. Siegbahn, and L. Wallentin Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: reply Eur. Heart J., July 2, 2007; 28(14): 1783 - 1783. [Full Text] [PDF]
|
|